Latest News and Press Releases
Want to stay updated on the latest news?
-
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related...
-
Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of...